New Building will Help Almac Serve Customers from Argentina to Zimbabwe
News Apr 10, 2012
Almac has opened a new £3m building at its Craigavon, UK headquarters from which staff will provide services to customers in over 100 countries around the world.
Around 150 staff who work for Almac’s Clinical Services Business Unit have just moved to the new 30,000 sq ft building to consolidate its services.
Staff working in the pharmaceutical development company’s new offices will co-ordinate and manage the processes involved in packaging and distribution of medicinal supplies for clinical studies carried out as far afield as Argentina to Zimbabwe.
Many of the staff are clinical Project Managers and Project Co-ordinators, managing studies on behalf of world-leading pharmaceutical and biotechnology companies.
Business Development, Marketing, Human Resources and Information Systems departments are also based in the new building.
Celine Bradley, Global VP of Operations said: “This addition to Almac’s continuously expanding headquarters brings together staff who have been working from different facilities on site for the past few years.
“Almac’s project staff manage clinical studies all around the world, providing cutting edge services that enhance the global clinical supply chain and contribute to the ethical goal of getting new treatments into the market faster.
“Investment in our staff, state of the art global facilities and ongoing delivery of innovative services positions Almac as the premium provider of clinical trial supply chain solutions.”
Carrying out the clinical studies requires specific manufacture, packaging and labelling to prepare bespoke packs for distribution around the world.
The company is constantly reviewing how to keep the drugs safe using its unique systems to monitor temperature conditions during transit and cut wastage.
Over 90% of Almac’s sales come from outside the UK and its global supply network now extends into 32 countries and 37 depots.
An immunotherapeutic antibody therapy re-educates macrophages to activate passivated cytotoxic T cells to kill cancer. The antibody therapy prevented the growth of tumors in several mouse models. The development of the therapy has now progressed to patient testing in a phase I/II clinical trial.READ MORE
15th International Conference on Surgical Pathology and Cancer Diagnosis
Apr 15 - Apr 16, 2019